Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Eltrombopag
Drug ID BADD_D00759
Description Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
Indications and Usage Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.
Marketing Status approved
ATC Code B02BX05
DrugBank ID DB06210
KEGG ID D03978
MeSH ID C520809
PubChem ID 135449332
TTD Drug ID D00PEH
NDC Product Code 47621-307
UNII S56D65XJ9G
Synonyms eltrombopag | Revolade | SB-497 115 | Promacta
Chemical Information
Molecular Formula C25H22N4O4
CAS Registry Number 496775-61-2
SMILES CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatic cirrhosis09.01.04.0010.000617%Not Available
Hepatic encephalopathy17.13.01.003; 09.01.03.0060.000229%Not Available
Hepatic failure09.01.03.0020.000915%
Hepatotoxicity09.01.07.009; 12.03.01.0080.000457%Not Available
Hyperbilirubinaemia14.11.01.010; 09.01.01.003; 01.06.04.0030.000343%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperthyroidism14.11.01.011; 05.02.02.0010.000229%
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Ileus07.13.01.0010.000229%
Immune system disorder10.02.01.0010.000617%Not Available
Increased tendency to bruise01.01.03.005; 24.07.06.012; 23.06.01.0090.000229%Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Influenza like illness08.01.03.0100.002332%
Insomnia19.02.01.002; 17.15.03.0020.008574%
Irritability19.04.02.013; 08.01.03.011--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.001235%Not Available
Joint swelling15.01.02.0040.004573%Not Available
Laryngeal pain22.12.03.010--
Leukaemia16.01.03.001; 01.10.03.0010.001143%
Liver disorder09.01.08.0010.002904%Not Available
Loss of consciousness17.02.04.004--Not Available
Lymphoma01.12.01.001; 16.20.01.0010.000229%Not Available
Malaise08.01.01.003--
Mass08.03.05.0030.000777%Not Available
Memory impairment19.20.01.003; 17.03.02.0030.003955%
Migraine24.03.05.003; 17.14.02.0010.005007%Not Available
Mood swings19.04.03.0010.002835%Not Available
Mouth haemorrhage24.07.02.014; 07.05.02.0010.000846%
Muscle spasms15.05.03.0040.007293%
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 9 Pages